الفهرس 
H EPATITIS C V IRUSOnly 14 pages are availabe for public view
 |  | from | 223 |  |  |
| | | from | 223 | | |
Abstract
ABSTRACT
Background: Hepatitis c virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis that frequently progress to a cirrhosis and hepatocellular carcinoma (HCC).
Objectives: The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment for prediction of liver fibrosis In Comparison with other markers of fibrosis (fib-4, APRI) score.
Patients and Methods: This prospective study was conducted on 50 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from different National Committee for Control of Viral Hepatitis (NCCVH) centers in Cairo during the period from January 2019 to June 2019, after informed consents were taken from the patients.
Results: This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment and there were significant positive correlations between serum autotoxin and Fib-4& APRI (baseline /12 weeks after treatment). ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity.
Conclusion: In our study. Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment in patients achieving a SVR. With improved overall liver function tests, liver enzymes and platelet count in patients who reached SVR and maintained negative PCR after treatment.